CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

The convenience store segment faced economic challenges in 2024 with shifting consumer preferences, consolidation, inflation ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Food companies are capitalizing on the GLP-1 trend, offering high-protein, portion-controlled meals. But are they meeting ...

The General Pharmaceutical Council (GPhC) has introduced new rules for weight-loss jabs, such as Wegovy and Mounjaro, in ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Britain's pharmacies regulator on Tuesday tightened rules for online pharmacies' prescribing obesity drugs, ordering them to ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.